{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:39:42Z","timestamp":1766504382415,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA252222","R01 CA244899"],"award-info":[{"award-number":["CA252222","R01 CA244899"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017450","name":"Icahn Institute for Data Science and Genomic Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017450","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018866","name":"Paula and Rodger Riney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bneo.2024.100049","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T18:09:56Z","timestamp":1728929396000},"page":"100049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-0151","authenticated-orcid":false,"given":"Rudra P.","family":"Dutta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-5136","authenticated-orcid":false,"given":"Santiago","family":"Thibaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-0601","authenticated-orcid":false,"given":"Violetta","family":"Leshchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghana","family":"Ram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Melnekoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2045-2357","authenticated-orcid":false,"given":"Paula","family":"Restrepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-3566","authenticated-orcid":false,"given":"Benjamin G.","family":"Barwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"McCafferty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feras","family":"Hantash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5757","authenticated-orcid":false,"given":"Hearn J.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larysa","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-8815","authenticated-orcid":false,"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-0564","authenticated-orcid":false,"given":"Alessandro","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bneo.2024.100049_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"10.1016\/j.bneo.2024.100049_bib2","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.bneo.2024.100049_bib3","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t (11; 14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.bneo.2024.100049_bib4","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Costa","year":"2021","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.bneo.2024.100049_bib5","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2024.100049_bib6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.bneo.2024.100049_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bneo.2024.100049_bib8","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","article-title":"Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1\u2013expressing myeloma cells","volume":"118","author":"Morales","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2024.100049_bib9","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V99.6.1885","article-title":"Myeloid cell factor\u20131 is a critical survival factor for multiple myeloma","volume":"99","author":"Zhang","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2024.100049_bib10","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","article-title":"Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma","volume":"67","author":"Gomez-Bougie","year":"2007","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.bneo.2024.100049_bib11","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bneo.2024.100049_bib12","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2024.100049_bib13","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1101\/gad.215855.113","article-title":"Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction","volume":"27","author":"Wang","year":"2013","journal-title":"Genes Dev"},{"issue":"5","key":"10.1016\/j.bneo.2024.100049_bib14","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41375-018-0374-8","article-title":"Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma","volume":"33","author":"Matulis","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bneo.2024.100049_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41408-022-00710-9","article-title":"Venetoclax ex\u00a0vivo functional profiling predicts improved progression-free survival","volume":"12","author":"Gupta","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.bneo.2024.100049_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.bneo.2024.100049_bib17","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1111\/febs.16136","article-title":"Understanding MCL1: from cellular function and regulation to pharmacological inhibition","volume":"289","author":"Sancho","year":"2022","journal-title":"FEBS J"},{"issue":"12","key":"10.1016\/j.bneo.2024.100049_bib18","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1101\/gad.215871.113","article-title":"Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure","volume":"27","author":"Thomas","year":"2013","journal-title":"Genes Dev"},{"issue":"8","key":"10.1016\/j.bneo.2024.100049_bib19","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41419-019-1831-7","article-title":"CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2\/BCL-XL inhibitor ABT-263","volume":"10","author":"Huang","year":"2019","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.bneo.2024.100049_bib20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/10428194.2023.2169045","article-title":"CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in\u00a0vitro and in\u00a0vivo","volume":"64","author":"Zhang","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.bneo.2024.100049_bib21","article-title":"THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors","volume":"8","author":"Cayrol","year":"2017","journal-title":"Nat Commun"},{"issue":"23","key":"10.1016\/j.bneo.2024.100049_bib22","first-page":"2841","article-title":"CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma","volume":"141","author":"Yao","year":"2023","journal-title":"Blood"},{"issue":"47","key":"10.1016\/j.bneo.2024.100049_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg9551","article-title":"Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications","volume":"7","author":"Bhalla","year":"2021","journal-title":"Sci Adv"},{"issue":"5","key":"10.1016\/j.bneo.2024.100049_bib24","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ccell.2019.04.005","article-title":"BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models","volume":"35","author":"Zhao","year":"2019","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.bneo.2024.100049_bib25","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-3788","article-title":"The covalent CDK7 inhibitor THZ1 potently induces apoptosis in multiple myeloma cells in\u00a0vitro and in\u00a0vivo","volume":"25","author":"Zhang","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7511","key":"10.1016\/j.bneo.2024.100049_bib26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nature13393","article-title":"Targeting transcription regulation in cancer with a covalent CDK7 inhibitor","volume":"511","author":"Kwiatkowski","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bneo.2024.100049_bib27","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"10.1016\/j.bneo.2024.100049_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2024.100049_bib29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ni.2527","article-title":"Mcl-1 is essential for the survival of plasma cells","volume":"14","author":"Peperzak","year":"2013","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100049_bib30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.bneo.2024.100049_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101015","article-title":"MCL-1 inhibition by selective BH3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes","volume":"23","author":"Rasmussen","year":"2020","journal-title":"iScience"},{"issue":"5","key":"10.1016\/j.bneo.2024.100049_bib32","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2012-03-415984","article-title":"Prolonged early G1 arrest by selective CDK4\/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle\u2013coupled loss of IRF4","volume":"120","author":"Huang","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2024.100049_bib33","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41375-019-0652-0","article-title":"A\u00a0novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies","volume":"34","author":"Phillips","year":"2020","journal-title":"Leukemia"},{"issue":"7626","key":"10.1016\/j.bneo.2024.100049_bib34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bneo.2024.100049_bib35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.semnephrol.2005.03.004","article-title":"Na,K-ATPase subunit heterogeneity as a mechanism for tissue-specific ion regulation","volume":"25","author":"Blanco","year":"2005","journal-title":"Semin Nephrol"},{"issue":"14","key":"10.1016\/j.bneo.2024.100049_bib36","doi-asserted-by":"crossref","first-page":"12209","DOI":"10.18632\/oncotarget.3528","article-title":"FKBPL: a marker of good prognosis in breast cancer","volume":"6","author":"Nelson","year":"2015","journal-title":"Oncotarget"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T02:58:41Z","timestamp":1762657121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2950328024000499"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100049","relation":{},"ISSN":["2950-3280"],"issn-type":[{"type":"print","value":"2950-3280"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100049"}}